Blog
How Long to Stop Ozempic Before Surgery? What the 2024 Guidance Actually Says
QUICK ANSWER
For most people, the answer is no longer a number of days. In October 2024, five medical societies replaced the blanket one-week hold with a risk-based approach. Most patients now continue their GLP-1 as prescribed before elective surgery. Higher-risk patients follow a liquid diet for 24 hours instead of stopping.
KEY TAKEAWAYS
- The old rule was to hold a weekly GLP-1 for one week and a daily one on the day of the procedure. That was 2023 guidance and it has been superseded.
- The October 2024 multisociety guidance says most patients should continue their GLP-1 before elective surgery.
- Higher risk means the dose escalation phase, active gastrointestinal symptoms, a higher dose, or another condition that slows stomach emptying.
- Highest risk patients follow a liquid diet for 24 hours before the procedure rather than stopping the medication.
- Elective surgery should be deferred until the escalation phase has passed, and until gastrointestinal symptoms have settled. Your surgical and anesthesia team decides. Never stop, hold or change a prescribed medication on your own.
If you have searched how long to stop Ozempic before surgery, you have probably been told one week. That advice came from a June 2023 consensus statement, and it was replaced in October 2024. Most pages online have not caught up.
This article explains what the current guidance says, why it changed, how to work out where you sit on the risk scale, and exactly what to tell your surgical team. It covers semaglutide and tirzepatide under every brand name, and it covers compounded versions, which almost nothing else online does.
| Before you read further: Do not stop, hold, delay or restart any prescribed medication based on an article. Your surgical and anesthesia team makes this decision using your medical history and the specific procedure. This page exists so you know what to ask them and what the current guidance says. |
How long to stop Ozempic before surgery, and what changed in 2024
| June 2023, ASA consensus guidance | October 2024, multisociety guidance | |
| Who issued it | American Society of Anesthesiologists | Five societies: the American Gastroenterological Association, the American Society for Metabolic and Bariatric Surgery, the American Society of Anesthesiologists, the International Society of Perioperative Care of Patients with Obesity, and the Society of American Gastrointestinal and Endoscopic Surgeons |
| Weekly medication | “For patients on weekly dosing consider holding GLP-1 agonists a week prior to the procedure/surgery.” | No fixed hold. Most patients continue as prescribed |
| Daily medication | “For patients on daily dosing consider holding GLP-1 agonists on the day of the procedure/surgery.” | No fixed hold. Most patients continue as prescribed |
| Did it vary by patient | No. It applied “irrespective of the indication (type 2 diabetes mellitus or weight loss), dose, or the type of procedure/surgery” | Yes. The decision is individualised on risk factors assessed before surgery |
| What high risk patients do | Hold the medication | Follow a liquid diet for 24 hours before the procedure |
| Evidence base | Described in the document itself as consensus based. It states the evidence was “sparse limited only to several case reports” | Developed jointly across five specialties after further study |
Sources: American Society of Anesthesiologists consensus based guidance on preoperative management of patients on GLP-1 receptor agonists, 29 June 2023. Multisociety Clinical Practice Guidance for the Safe Use of Glucagon-like Peptide-1 Receptor Agonists in the Perioperative Period, Clinical Gastroenterology and Hepatology, published online 29 October 2024.
Why did the guidance on stopping GLP-1s before surgery change?
This is the question nobody online answers, and it is the one that makes the rest make sense.
The 2023 guidance was written quickly, in response to case reports of patients aspirating stomach contents under anesthesia. GLP-1 medication slows gastric emptying, so the concern was reasonable. The problem was the evidence behind it. The document says so itself, describing the evidence as sparse and limited to several case reports.
A blanket hold has costs of its own. Someone with type 2 diabetes who stops loses glycemic control. Someone on a weight management program loses ground and may have to re-establish a dose. Procedures get delayed. Those costs land on every patient, while the aspiration risk the rule was designed to prevent turned out to be uncommon.
By late 2024, five societies covering anesthesia, gastroenterology, bariatric surgery and endoscopy concluded that a rule applied to everyone was the wrong shape for the problem. They replaced it with risk stratification. Identify the patients who actually have delayed gastric emptying, manage those patients differently, and leave everyone else on their medication.
| Worth knowing The October 2024 guidance does not announce itself as a reversal, and the societies did not publish a plain explanation of the change. That is a large part of why so much outdated content is still circulating, including on pages published in 2026. |
Are you at low, elevated or high risk?
The current approach turns on one question: is your stomach emptying normally right now? The guidance names four things that suggest it may not be.
| Risk level | What it looks like | What the guidance points toward |
| Lower risk | You have been on a stable dose for a while, you have no current gastrointestinal symptoms, and you have no other condition that slows gastric emptying | Continue the medication as prescribed. Standard preoperative fasting applies |
| Elevated risk | You are on a higher dose, or you have one risk factor present | Individual assessment. Your team may add a liquid diet, adjust the anesthesia plan, or use ultrasound to check stomach contents |
| Higher risk | You are in the dose escalation phase, which the guidance describes as lasting roughly four to eight weeks, or you have active nausea, vomiting, abdominal pain, constipation or shortness of breath | A liquid diet for 24 hours before the procedure. For active symptoms, the guidance says to wait until symptoms have settled before proceeding with elective surgery |
Source: American Society of Anesthesiologists, New Multi-Society GLP-1 Clinical Practice Guidance, 29 October 2024. Risk levels are a plain language summary of the factors named in that guidance, not a clinical scoring tool.
Two points are stated directly in the guidance and are easy to miss. Elective surgery should be deferred until the escalation phase has passed. And patients with gastrointestinal symptoms should wait until those symptoms have gone before proceeding with an elective procedure. In both cases the medication continues and the surgery moves, which is the opposite of the old approach.
If you are unsure whether your current symptoms count, our guide to GLP-1 side effects covers what is common and what is not.
What this means for your specific procedure
Not every procedure carries the same risk, because not every procedure involves the same airway protection. This is where most articles stop and where the practical answer actually lives.
| Procedure type | What generally applies | What to raise with your team |
| Elective surgery under general anesthesia | The October 2024 multisociety guidance applies directly. Most patients continue, with a liquid diet for 24 hours if higher risk | Your risk factors, your last dose date, and whether you are still escalating |
| Colonoscopy and upper endoscopy | Governed by gastroenterology guidance as well. The American Gastroenterological Association states it “does not endorse all patients stopping GLP-1s prior to endoscopy, but rather an individualized approach”. Bowel preparation quality is a separate issue from aspiration risk | Whether your prep needs to be extended, and whether a liquid diet replaces stopping |
| Joint replacement surgery | A 2025 orthopedic conference study reached a different conclusion. See the section below | Ask your surgeon which guidance the practice follows and why |
| Cosmetic and elective plastic surgery | The same multisociety guidance applies. Some practices still apply longer holds of two to four weeks based on the older advice | Ask which guidance the instruction is based on and what date it is from |
| Dental work or a procedure under local anesthetic only | No airway involvement means no aspiration risk under sedation, so this guidance is generally not the issue | Confirm whether any sedation is planned, because that changes the answer |
| Dental or minor procedures with IV sedation | Sedation affects airway reflexes, so the same considerations apply as for general anesthesia | Tell the sedation provider you take a GLP-1, the same as you would a surgeon |
| Emergency surgery | This guidance covers elective procedures. Emergency care is managed by the treating team with full stomach precautions | Nothing. Tell the team what you take and let them manage it |
Why one study says 14 days for joint replacement
If you have searched more than once you may have found a 2025 study presented at the American Academy of Orthopaedic Surgeons annual meeting recommending that GLP-1 medication be stopped at least 14 days before total joint replacement. It contradicts the multisociety guidance and no other page reconciles the two.
Three things are worth knowing. The outcome that study examined was delayed emergence from anesthesia, which is a different problem from aspiration. Joint replacement patients are a specific population, not a general one. And a study presented at a conference is a research finding, not clinical practice guidance issued by medical societies.
That does not make it wrong or irrelevant. It means your orthopedic surgeon may reasonably follow it. If you are having joint replacement and get a 14 day instruction, that is likely why, and it is worth asking about rather than assuming an error.
Which medication are you actually taking?
Six brand names map to two molecules, and preoperative forms often ask only about Ozempic. Knowing exactly what you take, and being able to say it clearly, matters more than any timing rule.
| What you take | Molecule | How often | What to tell the team |
| Ozempic | Semaglutide | Weekly injection | Name, dose in mg, and your last injection date |
| Wegovy | Semaglutide | Weekly injection | Same |
| Rybelsus, or Wegovy tablets | Semaglutide | Daily tablet | Say clearly that it is the oral form, because the old daily and weekly distinction still shapes some instructions |
| Mounjaro | Tirzepatide | Weekly injection | Name, dose in mg, and your last injection date |
| Zepbound | Tirzepatide | Weekly injection | Same |
| Saxenda or Victoza | Liraglutide | Daily injection | Say it is a daily injection |
| Compounded semaglutide | Semaglutide | Weekly injection | Say compounded semaglutide, give the dose in mg, and say it is not a branded product. See the section below |
| Compounded tirzepatide | Tirzepatide | Weekly injection | Say compounded tirzepatide, give the dose in mg, and say it is not a branded product |
If you are not sure how your two medications differ, our comparison of semaglutide and tirzepatide explains what each one does.
What to tell your surgical and anesthesia team
The single most useful thing you can do is give the team accurate information early. Most preoperative problems with GLP-1 medication are information problems, not drug problems.
The six details to bring
- The molecule, not just the brand. Semaglutide or tirzepatide.
- Whether it is branded or compounded.
- Your current dose in milligrams.
- The date of your last injection or tablet.
- Whether you are still increasing your dose, and when your last increase was.
- Any gastrointestinal symptoms you have had in the past week, including nausea, vomiting, abdominal pain, constipation or bloating.
Bring this to the preoperative appointment, not on the day. If the decision is to move the procedure or add a liquid diet, that needs lead time.
Being accurate about the last point matters. If you were told to follow a preoperative diet and did not manage it fully, say so. The anesthesia team can work with that. They cannot work around information they do not have.
If you take a compounded medication
This is the part almost no other page covers, and it causes real confusion at the preoperative desk.
Compounded semaglutide and compounded tirzepatide contain the same molecules as the branded products, but they are prepared by state licensed compounding pharmacies and they are not FDA approved. They do not carry a brand name your surgeon will recognise, and preoperative questionnaires often list only Ozempic or Wegovy by name.
If a form asks whether you take Ozempic and you take compounded semaglutide, the answer is not simply no. Write in what you take. The clinical question the form is trying to ask is whether you are on a GLP-1 medication, and you are.
Two practical points. Say the molecule name, because that is what a clinician recognises. And give your dose in milligrams rather than syringe units, because units are specific to the concentration in your vial and mean nothing to someone who has not seen it. Our guide to reading dose measurements in units and milligrams explains how to convert what is marked on your syringe.
| Provider and compliance review required before publishing This section describes what a patient should communicate about a compounded product. It should be checked against current AHC policy and against the regulatory position on compounded GLP-1 medication immediately before publishing. |
Is the answer different if you take it for diabetes rather than weight loss?
The guidance does not set different thresholds by indication. The consequences of stopping, however, are genuinely different, and that is what shapes the conversation.
| Type 2 diabetes | Weight management | |
| What holding the medication risks | Loss of glycemic control before and during a procedure, at a time when stable blood sugar matters | Appetite return, and losing ground on a dose you took months to reach |
| Who else is usually involved | The clinician managing your diabetes, alongside the surgical team | Your prescriber, alongside the surgical team |
| What the 2023 rule got wrong | It applied the same hold irrespective of indication, which meant diabetes patients absorbed a glycemic risk to prevent a rare aspiration risk | It treated a stable long term patient the same as someone in their first month |
In both cases the current approach is the same: assess the actual risk of delayed gastric emptying rather than applying a rule. If you take a GLP-1 for type 2 diabetes, make sure the clinician managing your diabetes is part of the decision.
What if you already took your dose and surgery is soon?
Tell your surgical team the date of your last dose and let them decide. Do not assume the procedure will be cancelled.
Under the current guidance, a recent dose is not by itself a reason to cancel. The team is assessing whether your stomach is emptying normally, and a stable patient with no symptoms is generally low risk regardless of when the last injection was. If they judge otherwise, the usual response is a liquid diet, an adjusted anesthesia plan, or an ultrasound check of stomach contents rather than cancellation.
What does cause problems is finding out late. A team that learns on the morning of surgery has fewer options than one that knew a week earlier.
Restarting after surgery, and whether you have to re-titrate
If you did hold your medication, restarting is a clinical decision made with your prescriber. Two things generally matter: that you are eating normally again without nausea, and that your digestive system is working normally.
The question nobody answers is whether you go back to the dose you were on. It depends mainly on how long the gap was. A short interruption is different from several weeks off, because tolerance to gastrointestinal side effects fades. After a longer gap, a prescriber may restart at a lower dose and build back up rather than resuming where you left off.
That is a provider decision and it is not something to work out yourself. Our article on restarting a GLP-1 after a break covers what the process involves.
If you are worried about losing progress during a hold, what happens when you stop taking a GLP-1 sets out what is documented. A hold of a week or two around a procedure is a very different thing from stopping treatment.
Frequently asked questions
How long do you have to stop Ozempic before surgery?
For most people, you do not. The October 2024 multisociety guidance replaced the fixed one-week hold with a risk-based approach, and most patients continue their medication before elective surgery. Higher-risk patients follow a liquid diet for 24 hours instead. Your surgical team makes the decision.
Why do some doctors still say to stop for a week?
The one-week hold came from June 2023 consensus guidance from the American Society of Anesthesiologists. It was replaced in October 2024, but the older advice is still widely published and some practices have not updated their protocols. If you are given a hold instruction, ask which guidance it is based on.
Does Ozempic interfere with anesthesia?
Semaglutide does not interact with anesthetic drugs. The concern is that it slows gastric emptying, so food may remain in the stomach longer than expected during fasting, which raises the risk of aspiration under sedation or general anesthesia.
Do I need to stop before a colonoscopy or endoscopy?
Not necessarily. The American Gastroenterological Association has stated it does not endorse all patients stopping GLP-1 medication before endoscopy and favours an individualised approach. Bowel preparation quality is a separate consideration from aspiration risk, so ask your gastroenterology team about both.
Do I need to stop before dental work?
It depends entirely on the anesthesia. A procedure under local anesthetic only does not involve the airway, so this guidance is generally not the issue. If IV sedation is planned, the same considerations apply as for surgery. Ask what type of sedation is being used.
What if I am still increasing my dose?
The dose escalation phase, described in the guidance as roughly four to eight weeks, is one of the named higher-risk factors. The guidance says elective surgery should be deferred until the escalation phase has passed. That means moving the procedure rather than stopping the medication.
Will my surgery be cancelled if I did not stop?
Not usually. Under current guidance a recent dose is not by itself a reason to cancel. The team is assessing your risk of delayed gastric emptying, and there are options short of cancellation including a liquid diet, an adjusted anesthesia plan, or an ultrasound check of stomach contents.
Can I just fast for longer instead of stopping?
That is close to what the current guidance actually recommends for higher-risk patients, which is a liquid diet for 24 hours before the procedure rather than stopping the medication. It is not something to decide yourself. Standard fasting instructions come from your surgical team and this would replace them, not add to them.
My surgeon says one thing and this guidance says another. Who do I follow?
Follow your surgical team. They know your history and the procedure. But it is reasonable to ask which guidance their instruction is based on and what date it is from, and to mention the October 2024 multisociety guidance if their answer is a flat one-week hold.
Do I need to stop compounded semaglutide before surgery?
The same clinical considerations apply, because the molecule is the same. The practical difference is communication. Your surgeon may not recognise a compounded product by name, so tell them the molecule, the dose in milligrams, and the date of your last injection rather than relying on a brand name on a form.
Is tirzepatide treated differently from semaglutide?
The multisociety guidance covers GLP-1 receptor agonists as a class and does not set separate rules by molecule. The relevant factors are the same: your dose, whether you are still escalating, and whether you currently have gastrointestinal symptoms.
Will I gain weight if I have to hold my medication?
A hold of a week or two around a procedure is different from stopping treatment. Documented weight regain data describes people who stopped and did not restart. If a longer hold is needed, discuss it with your prescriber, because that is a different conversation.
When can I restart after surgery?
When your prescriber says so, and generally once you are eating normally without nausea and your digestive system is working normally. Whether you resume your previous dose or restart lower depends on how long the gap was.
Where to go from here
If you have a procedure coming up, the useful next step is not a decision. It is a conversation, held early, with the six details from this article written down.
If you are considering treatment and want to understand what supervision involves, you can start a free evaluation with Alternate Health Club. A licensed US provider reviews your information individually and will tell you if treatment is not appropriate for you.
Medical disclaimer
This article is for general educational purposes and is not medical advice. It does not replace a consultation with a licensed healthcare professional, and it does not replace instructions from your surgical or anesthesia team. Compounded medications are not FDA approved and have not been reviewed by the FDA for safety, efficacy or quality. Brand names are used for educational identification only. Never stop, hold, delay, restart or change any medication without speaking to a qualified provider. If you have a procedure scheduled, contact your surgical team. Individual circumstances vary and no outcome is guaranteed.